Castroviejo-Bermejo, Marta <br/><br/>
A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation.  [electronic resource] 

 -  EMBO molecular medicine  12 2018 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1757-4684 
<br/><br/><label>Standard No.: </label>10.15252/emmm.201809172  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antineoplastic Agents--administration & dosage<br/>Biomarkers, Tumor--analysis<br/>Breast Neoplasms--diagnosis<br/>Drug Resistance, Neoplasm<br/>Female<br/>Heterografts--pathology<br/>Homologous Recombination<br/>Humans<br/>Mice<br/>Phthalazines--administration & dosage<br/>Piperazines--administration & dosage<br/>Poly(ADP-ribose) Polymerase Inhibitors--administration & dosage<br/>Rad51 Recombinase--analysis